2018
DOI: 10.18632/aging.101512
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Since early diagnosis is very important for treating CRC, we decided to detect peripheral serum canopy fibroblast growth factor signaling regulator 2 (CNPY2) isoform 2 to verify its diagnostic value for CRC patients. Serum samples were collected from 430 CRC patients and 201 healthy controls. Enzyme-linked immunosorbent assay (ELISA) detection kits for CNPY2 isoform 2 were generated and then applied to measure serum CNPY2 isoform 2 concentrations. Serum carcinoembryonic antigen (CEA) and carbohydrate antigen 1… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
4
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 26 publications
0
4
0
Order By: Relevance
“…CNPY2 may represent a prognostic indicator for CRC [ 31 ]. Serum CNPY2 is considered as a valuable diagnostic biomarker in CRC screening [ 32 ]. GRB10, which encodes an adaptor protein, modulates the coupling of multiple cell surface receptor kinases involved in specific signaling pathways.…”
Section: Discussionmentioning
confidence: 99%
“…CNPY2 may represent a prognostic indicator for CRC [ 31 ]. Serum CNPY2 is considered as a valuable diagnostic biomarker in CRC screening [ 32 ]. GRB10, which encodes an adaptor protein, modulates the coupling of multiple cell surface receptor kinases involved in specific signaling pathways.…”
Section: Discussionmentioning
confidence: 99%
“…Several genes have been identified to be dysregulated and associated with tumor progression in CRC. For example, serum CNPY2 isoform 2 was revealed to be upregulated in tumor samples and served as a novel biomarker for early detection of CRC (29). miR-6852 was downregulated and correlated with an improved prognosis for patients with CRC (30).…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, the relationship between these biomarkers and clinical features is also controversial (Dolscheid-Pommerich et al, 2017; Wild et al, 2010), which reduced their diagnostic and prognostic value in CRC. In recent years, a growing number of independent indicators in CRC have been explored, such as serum pentraxin-3 (Liu, Zhao & Guo, 2018), CNPY2 (Peng et al, 2018), and HSP-90 α (Kasanga et al, 2018), which have been of great help in the diagnosis and prognosis of CRC; however, the reliability of these biomarkers requires further study.…”
Section: Introductionmentioning
confidence: 99%